AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
Portfolio Pulse from Vandana Singh
AstraZeneca's cancer drug Imfinzi failed to meet the primary endpoint in a Phase 3 trial for early-stage lung cancer but succeeded in a Phase 3 bladder cancer study. The drug showed no new safety concerns and is being investigated in other lung cancer settings. Japan also approved AstraZeneca's Tagrisso for a specific type of lung cancer.
June 25, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Imfinzi failed in a Phase 3 trial for early-stage lung cancer but succeeded in a Phase 3 bladder cancer study. Japan also approved Tagrisso for a specific type of lung cancer. AZN shares were up 0.44%.
Despite the failure in the early-stage lung cancer trial, the success in the bladder cancer study and the approval of Tagrisso in Japan are positive developments. The stock price increase of 0.44% reflects investor optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100